Síndromes autoinflamatorios en edad adulta: reporte de 8 casos

IF 1.3 Q4 RHEUMATOLOGY

Reumatologia Clinica Pub Date : 2026-04-01 Epub Date: 2026-03-19 DOI:10.1016/j.reuma.2026.502126

Nuria Garvín Grande , Paloma Turiel Hernández , Manuel Beladiez Giner , Giancarlo Ernesto Candela Ganoza , Nicolás Silvestre Torner , Paz Collado Ramos

{"title":"Síndromes autoinflamatorios en edad adulta: reporte de 8 casos","authors":"Nuria Garvín Grande , Paloma Turiel Hernández , Manuel Beladiez Giner , Giancarlo Ernesto Candela Ganoza , Nicolás Silvestre Torner , Paz Collado Ramos","doi":"10.1016/j.reuma.2026.502126","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Retrospective study documenting the clinical features, demographic and analytical parameters and therapeutic management in a cohort of adult patients with AIS.</div></div><div><h3>Clinical description</h3><div>Eight patients (50% male) were included, the majority of whom were Caucasian. The most frequent AIS was AOSD (37.5%). The mean age at symptom onset was 40±23.1 years. The mean diagnostic delay was 5.7±5 years. Fever, skin rash and myalgias were the most prevalent symptoms. The mean CRP value was 187.1±110mg/L and ESR rate of 95.2±38mm/h. 100% were treated with systemic corticosteroids, 50% with int i-IL-1. Three patients required a switch from anakinra to canakinumab due to intolerance or lack of efficacy.</div></div><div><h3>Conclusions</h3><div>Given its increasing prevalence, this study emphasizes the importance of not underestimating the existence of AIS in adults, regardless of the level of health care. Early diagnosis and treatment with i-IL-1 are essential to control disease activity and prevent serious complications.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"22 4","pages":"Article 502126"},"PeriodicalIF":1.3000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X26000513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Retrospective study documenting the clinical features, demographic and analytical parameters and therapeutic management in a cohort of adult patients with AIS.

Clinical description

Eight patients (50% male) were included, the majority of whom were Caucasian. The most frequent AIS was AOSD (37.5%). The mean age at symptom onset was 40 ± 23.1 years. The mean diagnostic delay was 5.7 ± 5 years. Fever, skin rash and myalgias were the most prevalent symptoms. The mean CRP value was 187.1 ± 110 mg/L and ESR rate of 95.2 ± 38 mm/h. 100% were treated with systemic corticosteroids, 50% with int i-IL-1. Three patients required a switch from anakinra to canakinumab due to intolerance or lack of efficacy.

Conclusions

Given its increasing prevalence, this study emphasizes the importance of not underestimating the existence of AIS in adults, regardless of the level of health care. Early diagnosis and treatment with i-IL-1 are essential to control disease activity and prevent serious complications.

查看原文本刊更多论文

成人自身炎症综合征：8例报告

回顾性研究记录了一组成年AIS患者的临床特征、人口统计学和分析参数以及治疗管理。临床描述纳入8例患者（50%为男性），其中大多数为白种人。最常见的AIS是AOSD（37.5%）。平均发病年龄为40±23.1岁。平均诊断延迟为5.7±5年。发热、皮疹和肌痛是最常见的症状。CRP平均值为187.1±110 mg/L， ESR为95.2±38 mm/h。100%接受全身性皮质类固醇治疗，50%接受i-IL-1治疗。由于不耐受或缺乏疗效，3例患者需要从阿那单抗切换到canakinumab。结论：鉴于其日益增加的患病率，本研究强调了无论卫生保健水平如何，都不要低估成人AIS存在的重要性。用i-IL-1进行早期诊断和治疗对于控制疾病活动和预防严重并发症至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatologia Clinica RHEUMATOLOGY-

CiteScore

2.40

自引率

6.70%

发文量

105

审稿时长

54 days

期刊介绍： Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.